FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dana Hu-Lowe

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Procedures

Xenograft Model Antitumor Assays

Anatomy

Co-author Network

Publications

TOP 3
Dana Hu-Lowe; Nicoletta Brega; Shem Patyna
The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Weon-Kyoo You; Ian Kasman; Dana Hu-Lowe; Donald M McDonald
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.
Barbara Sennino; Frank Kuhnert; Sebastien Tabruyn; Michael R Mancuso; Dana Hu-Lowe; Calvin J Kuo; Donald M McDonald
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dana Hu-Lowe (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Dana Hu-Lowe; Nicoletta Brega; Shem Patyna
The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
Molecular cancer therapeutics 2011;10(11):2015.
2010: Weon-Kyoo You; Ian Kasman; Dana Hu-Lowe; Donald M McDonald
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.
The American journal of pathology 2010;176(4):1927-40.
2009: Barbara Sennino; Frank Kuhnert; Sebastien Tabruyn; Michael R Mancuso; Dana Hu-Lowe; Calvin J Kuo; Donald M McDonald
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Cancer research 2009;69(10):4527-36.
2007: Lisa J Wilmes; Maria G Pallavicini; Lisa M Fleming; Jessica Gibbs; Donghui Wang; Ka-Loh Li; Savannah C Partridge; Roland G Henry; David R Shalinsky; Dana Hu-Lowe; John W Park; Teresa M McShane; Ying Lu; Robert C Brasch; Nola M Hylton
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Magnetic resonance imaging 2007;25(3):319-27.
2006: Michael R Mancuso; Rachel Davis; Scott M Norberg; Shaun O'Brien; Barbara Sennino; Tsutomu Nakahara; Virginia J Yao; Tetsuichiro Inai; Peter Brooks; Bruce Freimark; David R Shalinsky; Dana Hu-Lowe; Donald M McDonald
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
The Journal of clinical investigation 2006;116(10):2610-21.
2006: Shem Patyna; A Douglas Laird; Dirk B Mendel; Anne-Marie O'Farrell; Chris Liang; Huiping Guan; Tomas Vojkovsky; Stefan Vasile; Xueyan Wang; Jeffrey Chen; Maren Grazzini; Cheng Y Yang; Joshua O Haznedar; Juthamas Sukbuntherng; Wei-Zhu Zhong; Julie M Cherrington; Dana Hu-Lowe
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Molecular cancer therapeutics 2006;5(7):1774-82.
2006: Tsutomu Nakahara; Scott M Norberg; David R Shalinsky; Dana Hu-Lowe; Donald M McDonald
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
Cancer research 2006;66(3):1434-45.
2006: Fabienne Baffert; Tom Le; Barbara Sennino; Gavin Thurston; Calvin J Kuo; Dana Hu-Lowe; Donald M McDonald
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
American journal of physiology. Heart and circulatory physiology 2006;290(2):H547-59.
2005: Young Ro Kim; Anna Yudina; Joseluis Figueiredo; Wilfried Reichardt; Dana Hu-Lowe; Alexander Petrovsky; Hye Won Kang; Denise Torres; Umar Mahmood; Ralph Weissleder; Alexei Bogdanov
Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
Cancer research 2005;65(20):9253-60.
2005: Ka-Loh Li; Lisa J Wilmes; Roland G Henry; Maria G Pallavicini; John W Park; Dana Hu-Lowe; Teresa M McShane; David R Shalinsky; Y-J Fu; Robert C Brasch; Nola M Hylton
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Journal of magnetic resonance imaging : JMRI 2005;22(4):511-9.
2005: Wilfried Reichardt; Dana Hu-Lowe; Denise Torres; Ralph Weissleder; Alexei Bogdanov
Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model.
Neoplasia (New York, N.Y.) 2005;7(9):847-53.
2004: Tetsuichiro Inai; Michael Mancuso; Hiroya Hashizume; Fabienne Baffert; Amy Haskell; Peter Baluk; Dana Hu-Lowe; David R Shalinsky; Gavin Thurston; George D Yancopoulos; Donald M McDonald
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
The American journal of pathology 2004;165(1):35-52.